<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6307">
  <stage>Registered</stage>
  <submitdate>17/01/2017</submitdate>
  <approvaldate>17/01/2017</approvaldate>
  <nctid>NCT03025542</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis</studytitle>
    <scientifictitle>A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-002368-15</secondaryid>
    <secondaryid>PS0016</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Plaque Psoriasis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Bimekizumab
Other interventions - Placebo

Experimental: Treatment Arm 1 - Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.

Experimental: Treatment Arm 2 - Subjects randomized in this arm will receive Bimekizumab injections.


Treatment: drugs: Bimekizumab
Based on their randomization subjects will receive a combination of several injections of Bimekizumab.

Other interventions: Placebo
Subjects will receive injections of Placebo.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from Baseline in Psoriasis Area and Severity Index (PASI) at Week 28</outcome>
      <timepoint>Week 28</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Mean plasma concentration of bimekizumab at Week 16</outcome>
      <timepoint>Week 16</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants reporting positive Anti-Drug-Antibodies (ADA) titre prior to and following study treatment with bimekizumab</outcome>
      <timepoint>From Baseline to the End of Treatment (Week 28)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of adverse events (AEs)</outcome>
      <timepoint>From Baseline to Safety Follow Up Visit (Week 36)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of subjects achieving a 75% or higher improvement from Baseline in PASI (Psoriasis Area and Severity Index) score at Week 16</outcome>
      <timepoint>Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of subjects achieving a 90% or higher improvement in PASI (Psoriasis Area and Severity Index) score at Week 16</outcome>
      <timepoint>Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of subjects achieving a 100% improvement from Baseline in PASI (Psoriasis Area and Severity Index) score at Week 16</outcome>
      <timepoint>Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects with IGA (InvestigatorÂ´s Global Assessment) response at Week 16</outcome>
      <timepoint>Week 16</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female at least 18 years of age and less than or equal to 70

          -  Chronic plaque psoriasis for at least 6 months prior to Screening

          -  Psoriasis Area and Severity Index (PASI) &gt;=12 and body surface area (BSA) &gt;=10% and
             Investigator's Global Assessment (IGA) score &gt;=3 on a 5-point scale

          -  Candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy

          -  Female subjects must be postmenopausal, permanently sterilized or, if of childbearing
             potential, must be willing to use a highly effective method of contraception up till
             20 weeks after last administration of study drug, and have a negative pregnancy test
             at Visit 1 (Screening) and immediately prior to first dose

          -  Male subjects with a partner of childbearing potential must be willing to use a condom
             when sexually active, up till 20 weeks after the last administration of study
             medication (anticipated 5 half-lives)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects previously participating in a bimekizumab study

          -  Subjects with erythrodermic, guttate, pustular form of psoriasis, or drug-induced
             psoriasis

          -  History of chronic or recurrent infections, or a serious or life-threatening infection
             within the 6 months prior to the Baseline Visit (including herpes zoster)

          -  High risk of infection in the Investigator's opinion

          -  Current sign or symptom that may indicate an active infection

          -  Concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus
             (HIV) infection

          -  Live (includes attenuated) vaccination within the 8 weeks prior to Baseline

          -  Subjects with concurrent malignancy or history of malignancy during the past 5 years
             (except for specific malignant condition as defined in the protocol)

          -  Primary immunosuppressive conditions

          -  TB infection, high risk of acquiring TB infection, latent TB infection (LTBI), or
             current or history of NTMB infection

          -  Laboratory abnormalities, as defined in the study protocol

          -  Any condition which, in the Investigator's judgement, would make the subject
             unsuitable for inclusion in the study

          -  Exposure to more than 1 biological response modifier (limited to anti-TNF or
             IL-12/-23) or any biologic response modifier during the three months prior to the
             Baseline Visit

          -  Subjects have received previous treatment with any anti-IL-17 therapy for the
             treatment of psoriasis or psoriatic arthritis

          -  Subjects with a diagnosis of inflammatory conditions other than psoriasis or psoriatic
             arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, or systemic
             lupus erythematosus. Subjects with a diagnosis of Crohn's disease or ulcerative
             colitis are allowed as long as they have no active symptomatic disease at Screening or
             Baseline

          -  Subjects taking psoriatic arthritis medications other than nonsteroidal
             anti-inflammatory drugs (NSAIDs) or analgesics</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>49</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Ps0016 102 - Kogarah</hospital>
    <hospital>Ps0016 101 - Melbourne</hospital>
    <hospital>Ps0016 104 - Woolloongabba</hospital>
    <postcode> - Kogarah</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ajax</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Windsor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Moldova, Republic of</country>
      <state>Chisinau</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>UCB Biopharma S.P.R.L.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Parexel</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to
      investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in
      adult subjects with moderate to severe chronic plaque psoriasis</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03025542</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>UCB Cares</name>
      <address>+1 844 599 2273(UCB)</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>